Jeffrey A MD Lieberman: Influence Statistics

Jeffrey A MD Lieberman

Jeffrey A MD Lieberman

Columbia University Irving Medical Center, New York, New York | New York State Psychiatric Institute, Department of Psychiatry, Columbia University Medical Center, New York | ...

Jeffrey A MD Lieberman: Expert Impact

Concepts for which Jeffrey A MD Lieberman has direct influence: Tardive dyskinesia , Weight gain , Episode schizophrenia , Chronic schizophrenia , Schizoaffective disorder , Patients schizophrenia , Antipsychotic drugs .

Jeffrey A MD Lieberman: KOL impact

Concepts related to the work of other authors for which for which Jeffrey A MD Lieberman has influence: Patients schizophrenia , Bipolar disorder , Negative symptoms , Weight gain , Metabolic syndrome , Mental health , Antipsychotic drugs .

KOL Resume for Jeffrey A MD Lieberman

Year
2022

Columbia University Irving Medical Center, New York, New York

2021

New York State Psychiatric Institute, New York, NY USA

2020

Department of Psychiatry, Columbia University, New York, New York

2019

Columbia University, Department of Psychiatry, New York State Psychiatric Institute (NYSPI), New York, NY, USA.

Department of Psychiatry, New York–Presbyterian Hospital, New York

2018

Research Foundation for Mental Hygiene, New York, NY, USA

Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York

2017

The New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, USA

Department of Psychiatry, Columbia University College of Physicians & Surgeons, New York, NY

2016

Department of Psychiatry, Columbia University, New York, New York, USA.

College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York, NY

New York Presbyterian Hospital−Columbia University Medical Center, New York

2015

Riverside Drive, Department of Psychiatry, Columbia University Medical Center, New York, NY 10032, USA

Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital, New York, New York

2014

The New York State Psychiatric Institute New York NY USA

Columbia University College of Physicians and Surgeons, New York, New York

2013

Department of Psychiatry, Columbia University Medical Center, New York, NY 10032, USA

Prominent publications by Jeffrey A MD Lieberman

KOL-Index: 18923 . IMPORTANCE: Multiple lines of evidence suggest a deficit in dopamine release in the prefrontal cortex (PFC) in schizophrenia. Despite the prevalence of the concept of prefrontal cortical hypodopaminergia in schizophrenia, in vivo imaging of dopamine release in the PFC has not been possible until now, when the validity of using the positron emission tomographic D2/3 radiotracer carbon ...
Known for Dopamine Release | Prefrontal Cortical | Positron Emission | Magnetic Resonance
KOL-Index: 17560 . BACKGROUND: In the treatment of schizophrenia, changing antipsychotics is common when one treatment is suboptimally effective, but the relative effectiveness of drugs used in this strategy is unknown. This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic. METHOD: Subjects ...
Known for Chronic Schizophrenia | Risperidone Olanzapine | Quetiapine Ziprasidone | Atypical Antipsychotic
KOL-Index: 16329 . OBJECTIVE: When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine. In this study, the authors compared switching to clozapine with switching to another atypical antipsychotic in patients who had discontinued treatment with a newer atypical antipsychotic in the context of ...
Known for Antipsychotic Treatment | Chronic Schizophrenia | Quetiapine Risperidone | Clozapine Patients
KOL-Index: 16167 . These guide lines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBO). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice ...
Known for Biological Treatment | Evidence Guidelines | Federation Societies | Drug Drug Therapy
KOL-Index: 14736 . Reduced NMDA receptor function is hypothesized to contribute to the pathophysiology of schizophrenia. In order to model chronic and developmental NMDA receptor hypofunction, a mouse line was developed that expresses low levels of the NMDA R1 subunit (NR1) of the NMDA receptor. The present study tested the hypothesis that these NR1 hypomorphic mice would exhibit deficits in sensorimotor and ...
Known for Sensorimotor Gating | Social Behavior | Nmda Receptor | Nr1 Mice
KOL-Index: 14511 . OBJECTIVE: Few long-term studies have compared the efficacy and safety of typical and atypical antipsychotic medications directly in patients with a first episode of psychosis who met the criteria for schizophrenia or a related psychotic disorder. This study compared the acute and long-term effectiveness of haloperidol with that of olanzapine in patients with first-episode psychosis in a ...
Known for Episode Psychosis | Olanzapine Patients | Versus Haloperidol | Comparative Efficacy
KOL-Index: 14415 . OBJECTIVE: Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments. METHOD: The authors examined the effects of clozapine, olanzapine, risperidone, and ...
Known for Cognitive Effects | Olanzapine Risperidone | Schizoaffective Disorder | Haloperidol Clozapine

Dopamine Partial Agonists


[ PUBLICATION ]
KOL-Index: 14390 . This review examines the development of dopamine partial agonists as a new class of antipsychotic agents. Partial agonists have a lower intrinsic activity at receptors than full agonists, allowing them to act either as a functional agonist or a functional antagonist, depending on the surrounding levels of naturally occurring neurotransmitter (full agonist). In the absence of a full ...
Known for Partial Agonists | Aripiprazole Treatment | Patients Schizophrenia | Agonist Activity
KOL-Index: 14365 . These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide ...
Known for Biological Treatment | Federation Societies | Updated Guidelines | Schizophrenia Management
KOL-Index: 14277 . One important risk factor for cardiovascular disease is the metabolic syndrome (MS), yet limited data exist on its prevalence in US patients with schizophrenia. METHODS: Using baseline data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial, assessment of MS prevalence was performed based on National Cholesterol Education Program (NCEP) ...
Known for Metabolic Syndrome | Intervention Effectiveness | Schizophrenia Trial | Clinical Antipsychotic
KOL-Index: 14199 . OBJECTIVE: This 52-week randomized, double-blind, flexible-dose, multicenter study evaluated the overall effectiveness (as measured by treatment discontinuation rates) of olanzapine, quetiapine, and risperidone in patients early in the course of psychotic illness. METHOD: Patients were randomly assigned to treatment with olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day), or ...
Known for Quetiapine Risperidone | Early Psychosis | Treatment Olanzapine | 52 Weeks
KOL-Index: 14095 . BACKGROUND: The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. METHODS: A total of 1493 patients with schizophrenia were ...
Known for Chronic Schizophrenia | Olanzapine Quetiapine | Antipsychotic Drugs | Risperidone Ziprasidone
KOL-Index: 14024 . These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. ...
Known for Biological Treatment | Guidelines Schizophrenia | Pregnancy Lactation | Substance Disorders
KOL-Index: 13960 . BACKGROUND: Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease, but their benefits are uncertain and concerns about safety have emerged. We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease. METHODS: In this 42-site, double-blind, ...
Known for Atypical Antipsychotic Drugs | Patients Alzheimers Disease | Treatment Psychosis | Aggression Agitation
KOL-Index: 13872 . Abstract These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These ...
Known for Biological Treatment | Federation Societies | Wfsbp Guidelines | Levels Evidence

Key People For Tardive Dyskinesia

Top KOLs in the world
#1
John Michael Kane
tardive dyskinesia patients schizophrenia bipolar disorder
#2
Dilip V MD Jeste
successful aging tardive dyskinesia mental health
#3
Nina R Schooler
negative symptoms schizoaffective disorder episode psychosis
#4
Jeffrey A MD Lieberman
tardive dyskinesia weight gain episode schizophrenia
#5
Daniel E Casey
tardive dyskinesia weight gain extrapyramidal syndromes
#6
Richard Jed Wyatt
tardive dyskinesia schizophrenic patients chronic schizophrenia

Columbia University Irving Medical Center, New York, New York | New York State Psychiatric Institute, Department of Psychiatry, Columbia University Medical Center, New York | Department of Psychiatry, Columbia University, New York, NY, USA. | New Yor